FIIs Bought 13.34 Per Cent & DIIs Increase Stake: Multibagger Penny Stock Under Rs 60 Approves Acquisition of India’s First Deep-Tech AI Software Platform
FIIs Bought 13.34 Per Cent & DIIs Increase Stake: Multibagger Penny Stock Under Rs 60 Approves Acquisition of India’s First Deep-Tech AI Software Platform
The stock is up by 47 per cent from its 52-week low of Rs 41.01 per share.
The stock is up by 47 per cent from its 52-week low of Rs 41.01 per share.
Ashish Kacholia Backed Multibagger Power Transmission Stock Surges Over 5 Per Cent in Intraday After Securing L1 Bid For PGVCL Turnkey Contract
In the last five years, the stock has given multibagger returns of 5,000 per cent.
In the last five years, the stock has given multibagger returns of 5,000 per cent.
16,000 Per Cent Returns & FII Stake Increases: Battery Maker Commissions 3.2 GW Plant, Orders Robotic Line; Eyes 2nd 3.2 GW Unit in South India After 5-Site Evaluation
In the last five years, the stock price has logged multibagger returns of 16,342 per cent.
In the last five years, the stock price has logged multibagger returns of 16,342 per cent.
FIIs & DIIs Increases Stake: This Solar Energy Company Announces Strategic Tie-Up With RENA Technologies To Boost Solar Cell Innovation
Foreign Institutional Investors (FIIs) increased their stake slightly to 2.95 per cent from 2.31 per cent in December 2024. Domestic Institutional Investors (DIIs) also raised their holding to 8.66 per cent, up from 7.95 per cent.
Foreign Institutional Investors (FIIs) increased their stake slightly to 2.95 per cent from 2.31 per cent in December 2024. Domestic Institutional Investors (DIIs) also raised their holding to 8.66 per cent, up from 7.95 per cent.
Sensex and Nifty Jump After Long Weekend on Global Cues
Broader indices, including small-cap and mid-cap stocks, moved up, gaining 1.3 per cent each.
The Indian Biotech Leader Expands its Operations in the U.S. Strategically Through the Launch of a New Biosimilar
The Indian Biotech Leader Expands its Operations in the U.S. Strategically Through the Launch of a New Biosimilar
Over the past year, Biocon delivered a return of 15.51 per cent, while its three-year return stood at -9.75 per cent.
Over the past year, Biocon delivered a return of 15.51 per cent, while its three-year return stood at -9.75 per cent.
Top three stocks that saw heavy demand from buyers in the pre-opening session today
These three stocks were the top gainers on BSE in the pre-opening session today.
These three stocks were the top gainers on BSE in the pre-opening session today.
Peer Company of Ola Electric, Revolt Motors, Begins Operations in Nepal with First Dealership in Kathmandu
The stock has delivered a remarkable 2,000 per cent multibagger return in 5 years. Investors should monitor this Small-Cap company closely.
The stock has delivered a remarkable 2,000 per cent multibagger return in 5 years. Investors should monitor this Small-Cap company closely.
2,000 Per cent Returns: Poonawala Backed NBFC Launches Gold Loan Business
In the last one year the stock price has given negative 23 per cent return while in 5 years it has given multibagger returns of 2,040 per cent.
In the last one year the stock price has given negative 23 per cent return while in 5 years it has given multibagger returns of 2,040 per cent.
Markets Poised for Gap-Up Start as Tech Rally and Tariff Easing Lift Global Markets
On April 11, 2025, foreign institutional investors (FII) sold shares worth Rs 2,519.03 crore, while domestic institutional investors (DII) bought shares worth Rs 3,759.27 crore.
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP
Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg.
The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.
3,400 Per Cent Multibagger Returns; Board Announces 1:1 Bonus Share; Check Record Date Inside
The stock gave multibagger returns of 185 per cent in 1 just 1 year and a whopping 3,400 per cent returns in 5 years.
The stock gave multibagger returns of 185 per cent in 1 just 1 year and a whopping 3,400 per cent returns in 5 years.